Clinical trialNCT02292758CompletedPhase 2Interventional

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

SponsorAcademic and Community Cancer Research UnitedEnrollment36Colorectal AdenocarcinomaRAS Wild TypeStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally advanced/metastatic) and cannot be removed by surgery. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as cetuximab and bevacizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving irinotecan and cetuximab with or without bevacizumab may work betting in treating patients with colorectal cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kimmie Ng
Academic and Community Cancer Research United
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Saint Luke'S Mountain States Tumor Institute
Boise, Idaho, United States
Siouxland Regional Cancer Center
Sioux City, Iowa, United States
Cancer Center of Kansas - Wichita
Wichita, Kansas, United States
Ochsner Medical Center Jefferson
New Orleans, Louisiana, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Michigan Cancer Research Consortium Ncorp
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Heartland Regional Medical Center
Saint Joseph, Missouri, United States
Missouri Baptist Medical Center
St Louis, Missouri, United States
New Hampshire Oncology Hematology Pa-Hooksett
Hooksett, New Hampshire, United States
State University of New York Upstate Medical University
Syracuse, New York, United States
Saint Vincent Regional Cancer Center Ccop
Green Bay, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →Cetuximab →Irinotecan →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Dec 2014
Primary completion: 20 Mar 2019
Completion: 27 Sept 2019
Last update posted: 31 Jan 2022
Registered enrollment: 36
Registry id: NCT02292758

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.